TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Billy Joel announced his first official show since being diagnosed with normal pressure hydrocephalus, according to a report by MedPage Today citing People. The same neurology roundup summarized studies linking slow-wave sleep with cognitive trajectories in preclinical Alzheimer’s disease and identifying factors associated with faster Parkinson’s progression.
Billy Joel has announced his first official show since his diagnosis of normal pressure hydrocephalus, according to a November 10 MedPage Today neurology roundup citing People. The roundup also covered research associating slow-wave sleep with cognitive trajectories in preclinical Alzheimer’s disease and certain characteristics at diagnosis with faster Parkinson’s disease progression.
The report identifies Joel’s announcement as a return to performing after his diagnosis, but does not give the show’s date, venue, or further details about his health. The announcement is attributed to People; MedPage Today’s item does not reproduce a direct statement from Joel or his representatives.
On Alzheimer’s disease, the roundup describes a study finding that slow-wave sleep was linked to cognitive trajectories among people with preclinical disease. The researchers reported that the associations may have been stronger in men. The summary does not provide effect sizes or details that would establish whether sleep changes cause differences in cognition.
A separate Italian cohort study, published in the Journal of Neurology, Neurosurgery & Psychiatry, associated older age, bilateral symmetric parkinsonism, and rapid eye movement sleep behavior disorder at diagnosis with faster Parkinson’s disease progression. These are associations from a cohort study, not a definitive forecast for an individual patient.
Joel’s Return and Neurology Research
Joel’s announcement is a public update on a major performer’s return after a health diagnosis, though the available report leaves practical details about the performance unanswered. For fans, the key confirmed point is that he has announced an official show; the source does not establish when it will happen or describe any conditions attached to his return.
The research findings matter for a different reason: they add to evidence about factors associated with cognitive change and Parkinson’s progression. Neither summary establishes cause and effect, and the reported Parkinson’s characteristics should not be treated as a personal prognosis. The studies may inform further research and clinical discussion, but the roundup alone does not support treatment recommendations.
Products Worth Considering
Philips Sonicare 6500 Series Rechargeable Electric Toothbrush with 2 Brush Heads, White
Coway Airmega AP-1512HHS Smart Air Purifier, Black
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
The Studies Behind the Roundup
MedPage Today’s November 10 report was a brief roundup of developments in neurology and neuroscience, rather than a single study or a detailed account of Joel’s diagnosis. It brought together his performance announcement with research on several conditions, including Alzheimer’s disease and Parkinson’s disease.
The Alzheimer’s finding concerns people described as having preclinical Alzheimer’s disease, a stage before symptoms are apparent. The Parkinson’s result came from an Italian cohort study. The source summary does not provide the number of participants, follow-up period, or measures used to define faster progression, so those details cannot be assessed from the report alone.
Show Details and Study Limits
The roundup does not state when or where Joel’s show will take place, whether additional dates are planned, or what he has said directly about performing after his diagnosis. It also provides no further medical update, so his current health status should not be inferred from the announcement.
For both studies, the summary leaves important methods and results unspecified. It gives no numerical estimates for the sleep-cognition association or the Parkinson’s progression findings. The reported link between slow-wave sleep and cognitive trajectories does not show that changing sleep would alter Alzheimer’s risk or progression. Likewise, the Parkinson’s associations do not determine how quickly any one person’s disease will progress.
Awaiting Performance and Research Details
The next details to watch for are the date, venue, and any further information about Joel’s performance, which were not included in the source report. No additional show announcement or schedule was specified.
For the research, full study publications and follow-up work would be needed to clarify the size and reliability of the reported associations. The roundup does not identify a next milestone for either study, nor does it report a change to clinical guidance based on the findings.
Key Questions
What did Billy Joel announce?
He announced his first official show since his normal pressure hydrocephalus diagnosis, according to MedPage Today’s report citing People.
When is Billy Joel’s show?
The source report does not provide a date or venue.
What did the Alzheimer’s study find?
It linked slow-wave sleep with cognitive trajectories in people with preclinical Alzheimer’s disease. The association may have been stronger in men, according to the roundup; this does not establish that sleep changes cause cognitive changes.
Which factors were associated with faster Parkinson’s progression?
An Italian cohort study associated older age, bilateral symmetric parkinsonism, and rapid eye movement sleep behavior disorder at diagnosis with faster progression. The findings are group-level associations, not an individual prediction.
Source: medpagetoday.com
